Which peptides are studied for weight and metabolic conditions?

Short answer

32 profiles here are grouped under “Metabolic and weight”: 15 FDA-approved, 1 approval reported abroad, 11 in clinical trials and 5 not FDA-approved.

Each entry below quotes its profile and links to the full answer there.

FDA-approved 15

Approval reported abroad 1

In clinical trials 11

Not FDA-approved 5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  5. 5
    Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Exenatide injection · SPL version 17 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  7. 7
    Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  9. 9
    Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  10. 10
    Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  11. 11
    GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  12. 12
    Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  13. 13
    Drugs@FDA application NDA210134 · original submission status AP · 2019-07-24 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  14. 14
    Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  15. 15
    LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  16. 16
    Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  17. 17
    Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  18. 18
    Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  19. 19
    Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  20. 20
    Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  21. 21
    Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  22. 22
    Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  23. 23
    ADLYXIN, revised November 2024: U.S. prescribing information ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  24. 24
    SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  25. 25
    Drugs@FDA: MYALEPT (metreleptin), application 125390 · original approval February 24, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  26. 26
    MYALEPT (metreleptin) for injection · SPL version 18 · published 2025-03-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  27. 27
    Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  28. 28
    FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  29. 29
    SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  30. 30
    Drugs@FDA application NDA021332 · original submission status AP · 2005-03-16 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  31. 31
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  32. 32
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  33. 33
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  34. 34
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  35. 35
    IMCIVREE (setmelanotide) solution · SPL version 14 · published 2026-04-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  36. 36
    Drugs@FDA application NDA213793 · original submission status AP · 2020-11-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  37. 37
    EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  38. 38
    Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  39. 39
    ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026

  40. 40
    Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  41. 41
    Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  42. 42
    June 27, 2025 government report of Chinese approval for mazdutide weight management ↗

    Suzhou Industrial Park Market Supervision Bureau · Official source · Source checked September 15, 2026

  43. 43
    December 19, 2025 government report describing Chinese mazdutide diabetes and weight indications ↗

    Suzhou Municipal Government · Official source · Source checked September 15, 2026

  44. 44
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  45. 45
    Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  46. 46
    Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗

    The Lancet · Official source · Source checked November 14, 2026

  47. 47
    ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  48. 48
    ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  49. 49
    ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  50. 50
    ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  51. 51
    ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  52. 52
    ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗

    ClinicalTrials.gov · Official source · Source checked November 15, 2026

  53. 53
    Avexitide acetate substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  54. 54
    PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026

  55. 55
    Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗

    Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026

  56. 56
    Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  57. 57
    ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  58. 58
    Cotadutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  59. 59
    Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗

    Diabetes Care · Official source · Source checked November 15, 2026

  60. 60
    Efpeglenatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  61. 61
    ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  62. 62
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  63. 63
    Eloralintide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  64. 64
    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗

    The Lancet · Official source · Source checked November 15, 2026

  65. 65
    Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  66. 66
    ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  67. 67
    ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78 ↗

    ClinicalTrials.gov · Official source · Source checked August 13, 2026

  68. 68
    Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  69. 69
    ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  70. 70
    ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  71. 71
    ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  72. 72
    Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  73. 73
    ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗

    ClinicalTrials.gov · Official source · Source checked November 14, 2026

  74. 74
    BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  75. 75
    ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  76. 76
    Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗

    Obesity · Official source · Source checked November 16, 2026

  77. 77
    ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  78. 78
    5-Amino-1-methylquinolinium substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  79. 79
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  80. 80
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  81. 81
    FDA briefing document for MOTS-c ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  82. 82
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  83. 83
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  84. 84
    SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  85. 85
    Tesofensine substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026